# Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06560632/  
OnCo record `nct06560632` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of RP-3467 run by Repare Therapeutics, terminated.

## Summary

Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06560632 by Repare Therapeutics, with 26 participants enrolled, started 2024-09-17. Conditions recorded: Advanced Solid Tumor. Interventions recorded: RP-3467 at assigned dose and schedule and Olaparib 200-300 mg BID, daily.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06560632
- Phase: 1
- Setting: Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR Trial)
- Sponsor: Repare Therapeutics
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT06560632: https://clinicaltrials.gov/study/NCT06560632

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [RP-3467](https://onco.cc/drugs/rp-3467/)
- companies: [Repare Therapeutics](https://onco.cc/companies/repare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06560632.json